Table 1.
Main clinico‐pathological parameters of the MMPs included in this study
| Variables | Patients n (%) |
|---|---|
| Gender | |
| Male | 78 (61%) |
| Female | 50 (39%) |
| Age (years) | |
| Median (min – max) | 57 (18 – 85) |
| Primary tumor site | |
| Head and neck | 24 (19%) |
| Limbs | 54 (42%) |
| Trunk | 29 (22%) |
| Hands or feet | 15 (11%) |
| Unknown | 8 (6%) |
| Histology | |
| SSM | 34 (27%) |
| NM | 65 (51%) |
| LMM | 5 (4%) |
| ALM | 12 (9%) |
| Others | 12 (9%) |
| Ulceration | |
| Absent | 30 (23%) |
| Present | 98 (77%) |
| Metastatic sites | |
| Regional lymph nodes | 32 (25%) |
| Lung | 13 (10%) |
| Brain | 12 (9%) |
| Liver | 6 (5%) |
| Disseminated | 65 (51%) |
| AJCC staging | |
| IIIb | 17 (13%) |
| IIIc | 23 (18%) |
| IV | 88 (69%) |
| M1a | 32 (25%) |
| M1b | 21 (16.5%) |
| M1c | 35 (27.5%) |
SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo malignant melanoma; ALM, acral lentiginous melanoma; AJCC, American Joint Committee on Cancer.